According to the new market research report "Human Microbiome Market by Product (Prebiotics, Probiotics, Food, Diagnostic Tests, Drugs), Application (Therapeutic, Diagnostic), Disease (Infectious, Metabolic/Endocrine), Research Technology (Genomics, Proteomics, Metabolomics) - Global Forecast to 2028" The human microbiome market is projected to reach USD 1,598 million by 2028 from USD 894 million in 2025, at a CAGR of 21.3% from 2025 to 2028.
Browse and in-depth TOC on "Human Microbiome Market"
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904
Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is also expected to offer a wide range of growth opportunities for market players during the forecast period.
The drugs segment to account for the largest share of the product segment in the global human microbiome market in 2024
Based on product, the human microbiome market is segmented into probiotics, prebiotics, diagnostic tests, drugs, and other products. The drugs segment is expected to account for the largest share of the human microbiome market in 2024. The large share of this segment can be attributed to the increasing number of human microbiome-based drug products in clinical trials and rising funding to develop microbiome-based drugs.
The therapeutics segment to account for the largest share of the market in 2024
Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The therapeutics segment is expected to dominate the market in 2024. The increase in funding for R&D in microbiome-based therapies worldwide is the major factor driving the growth of this application segment. Technological advancements, the increasing number of clinical trials for the diagnostics segment, and growing collaborations between key market players and research institutes also support market growth.
The infectious diseases segment to account for the largest share of the market in 2024
Based on disease, the human microbiome market is segmented into five categories—infectious diseases, metabolic disorders, gastrointestinal diseases, cancer, and other diseases. The infectious diseases segment is expected to account for the largest share of the global human microbiome market in 2024. The large share of this segment can be attributed to the increasing research in microbiome-based products and their use in treating infectious diseases. The major focus is on developing products targeting the microbiome modulators for infectious diseases, which accounts for 40-50 products currently in the pipeline.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904
The Asia Pacific region is the fastest growing region of human microbiome research spending market in 2019
On the basis of region, the global human microbiome research spending market is segmented into four major geographies— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of the global human microbiome research spending market in 2019. In 2019, the Asia Pacific region is estimated to grow at the highest CAGR in the human microbiome research spending from 2020-2025. Factors such as increasing focus on microbiome research and initiatives taken by public and private organizations to increase awareness regarding microbiome therapeutics, are driving the growth of the human microbiome market in the Asia Pacific (APAC) region.
The major players in the human microbiome market include Enterome Bioscience (France), Seres Therapeutics (US) 4D Pharma (UK), and Ferring Pharmaceuticals (Switzerland).
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=37621904
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
Email: [email protected]
Content Source: https://www.marketsandmarkets.com/PressReleases/human-microbiome.asp
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/clinical-trial-supplies-market.asp